Positive donor and negative recipient cytomegalovirus status is a detrimental factor for long-term renal allograft survival.
In 524 allogeneic cadaveric kidney transplants, the impact of cytomegalovirus (CMV) donor/recipient status on the incidence of CMV infection, CMV disease, early and long-term graft, and patient survival have been analyzed with respect to rejection episodes. Most CMV infections (59%) and diseases (17%) were found in CMV-negative recipients of CMV-positive kidneys. The 1-year function rate of CMV-positive kidneys (75%) dropped about 10% below that of CMV-negative organs (85%), and in the case of CMV-negative recipients an additional graft loss of more than 10% happened within the 4th and 5th years (5-year graft survival pos./neg.: 56%). This detrimental effect was exaggerated if it coincided with antibody-treated rejection episodes.
Petersen
P
P
Department of Transplant Surgery, Ludwig-Maximilians-Universität, Munich, Germany.
Schneeberger
H
H
Schleibner
S
S
Illner
W D
WD
Hofmann
G O
GO
Land
W
W
D000328:Adult; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000503:physiopathology*; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology*; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D014019:Tissue Donors; D017211:Treatment Failure; D016896:Treatment Outcome
D007166:Immunosuppressive Agents